ATE192653T1 - Anwendungen von acemannan - Google Patents

Anwendungen von acemannan

Info

Publication number: ATE192653T1
Authority: AT; Austria
Prior art keywords: acemannan; defective virus; master seed; production; medicament
Prior art date: 1988-08-05

Application number

AT94105182T

Other languages

English (en)

Inventor

Bill H Mcanalley

Robert H Carpenter

Harley R Mcdaniel

Original Assignee

Carrington Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-05

Filing date

1989-08-03

Publication date

2000-05-15

1989-08-03 Application filed by Carrington Lab Inc filed Critical Carrington Lab Inc

2000-05-15 Application granted granted Critical

2000-05-15 Publication of ATE192653T1 publication Critical patent/ATE192653T1/de

Links

XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 title abstract 3
229960005327 acemannan Drugs 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
241000700605 Viruses Species 0.000 abstract 2
230000002950 deficient Effects 0.000 abstract 2
238000011218 seed culture Methods 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
230000029812 viral genome replication Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Natural Medicines & Medicinal Plants (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Mycology (AREA)
Polymers & Plastics (AREA)
Materials Engineering (AREA)
Botany (AREA)
General Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Alternative & Traditional Medicine (AREA)
Biomedical Technology (AREA)
Medical Informatics (AREA)
Virology (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT94105182T 1988-08-05 1989-08-03 Anwendungen von acemannan ATE192653T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/229,164 US5106616A (en)	1988-01-14	1988-08-05	Administration of acemannan

Publications (1)

Publication Number	Publication Date
ATE192653T1 true ATE192653T1 (de)	2000-05-15

Family

ID=22860075

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT89910539T ATE115405T1 (de)	1988-08-05	1989-08-03	Aloe-zusammensetzungen und deren verwendungen.
AT94105182T ATE192653T1 (de)	1988-08-05	1989-08-03	Anwendungen von acemannan

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT89910539T ATE115405T1 (de)	1988-08-05	1989-08-03	Aloe-zusammensetzungen und deren verwendungen.

Country Status (8)

Country	Link
US (1)	US5106616A (de)
EP (4)	EP0857485A3 (de)
JP (1)	JP2888249B2 (de)
AT (2)	ATE115405T1 (de)
AU (1)	AU637985B2 (de)
CA (1)	CA1336581C (de)
DE (2)	DE68920019T2 (de)
WO (1)	WO1990001253A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106616A (en) *	1988-01-14	1992-04-21	Carrington Laboratories, Inc.	Administration of acemannan
US5468737A (en) *	1982-05-07	1995-11-21	Carrington Laboratories, Inc.	Wound healing accelerated by systemic administration of polysaccharide from aloe
US5308838A (en) *	1982-05-07	1994-05-03	Carrington Laboratories, Inc.	Uses of aloe products
US6136788A (en) *	1987-12-30	2000-10-24	Cytran, Inc.	Pharmaceutical preparation for the therapy of immune deficiency conditions
US5814611A (en) *	1988-12-14	1998-09-29	Cytoven J.V.	Pharmaceutical for the therapy of immune deficiency conditions
US5658957A (en) *	1991-03-01	1997-08-19	Warner Lambert Company	Immunostimulating wound healing compositions and method for preparing and using same
WO1993008810A1 (en) *	1991-11-05	1993-05-13	Carrington Laboratories, Inc.	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
ZA93216B (en) *	1992-01-17	1993-08-18	Solvay Animal Health Inc	Vaccine containing acemannan as an adjuvant.
US5409703A (en) *	1993-06-24	1995-04-25	Carrington Laboratories, Inc.	Dried hydrogel from hydrophilic-hygroscopic polymer
US5902796A (en) *	1995-09-22	1999-05-11	Carrington Laboratories, Inc.	Bioactive factors of aloe vera plants
US5858378A (en) *	1996-05-02	1999-01-12	Galagen, Inc.	Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6929807B1 (en) *	1996-08-09	2005-08-16	Mannatech, Inc.	Compositions of plant carbohydrates as dietary supplements
JP5020424B2 (ja) *	1996-08-09	2012-09-05	マナテック・インコーポレイテッド	食物補強剤としての植物炭水化物の組成物
US6303584B1 (en)	1996-11-20	2001-10-16	The University Of Montana	Water soluble lipidated arabinogalactan
CU22629A1 (es) *	1997-03-06	2000-12-22	Ct Ingenieria Genetica Biotech	Formulaciones inmunopotenciadoras para uso vacunal
KR100678238B1 (ko) *	1997-10-10	2007-02-01	유니젠 파아마슈티컬스,인크.	알로에로부터 면역조절성 다당류를 제조하는 방법
US6136794A (en) *	1998-02-02	2000-10-24	Merck & Co., Inc.	Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
CU22740A1 (es) *	1998-09-07	2002-02-28	Ct Ingenieria Genetica Biotech	Formulación de ácidos nucleicos y acemanano
US7494669B2 (en)	2001-02-28	2009-02-24	Carrington Laboratories, Inc.	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20030175370A1 (en) *	2002-03-07	2003-09-18	Carrington Laboratories, Inc.	Dispersed solid-containing complex carbohydrate
US6884783B2 (en) *	2002-05-03	2005-04-26	Unigen Pharmaceuticals, Inc.	7-Hydroxy chromones as potent antioxidants
US7060304B2 (en) *	2003-04-16	2006-06-13	Access Business Group International Llc	Skin whitening compositions containing black cohosh extract
WO2005030232A2 (en) *	2003-07-14	2005-04-07	Shambabu Ayare	Herbal compositions for effective treatment of aids, preparation thereof and method for treatment of aids patients
EP2286845B1 (de) *	2004-03-05	2016-11-16	Gen-Probe Incorporated	Reagentien und Verfahren zur Deaktivierung von Nukleinsäuren
WO2005095463A1 (en)	2004-03-26	2005-10-13	Glycogenesys, Inc.	Modified pectins, compositions and methods related thereto
EP1736773B1 (de) *	2004-04-16	2014-07-02	Ajinomoto Co., Inc.	Testen der potency einer peripheren mononukleären blutzelle zur bindung an polysaccharid
KR100720973B1 (ko) *	2005-03-18	2007-05-22	주식회사 유니젠	천연물 유래 아이소오리엔틴을 포함하는 히스타민 억제용약학 조성물
WO2007024589A2 (en) *	2005-08-24	2007-03-01	The Trustees Of Columbia University In The City Of New York	Phagocyte enhancement therapy for atherosclerosis
WO2007044936A2 (en) *	2005-10-13	2007-04-19	The University Of Mississippi	Animal model of anxiety and depression
US8999293B2 (en)	2005-10-13	2015-04-07	University Of Mississippi	Animal model of anxiety and depression
US20070275150A1 (en) *	2006-05-26	2007-11-29	Ciell Michael P	Nutritional composition and method of making the same
SI2022786T1 (sl) *	2006-05-31	2012-04-30	Toyama Chemical Co Ltd	Sredstvo proti virusu slinavke in parkljevke za ĺ˝ival, pripadajoäśo druĺ˝ini suidae, ali ovco in postopek za prepreäśevanje ali zdravljenje slinavke in parkljevke pri ĺ˝ivali, pripadajoäśi druĺ˝ini suidae, ali ovci
TWI454261B (zh)	2007-01-09	2014-10-01	猶尼根公司	作為治療劑之色酮類
CA2687063C (en) *	2007-05-11	2017-04-04	Aloebiotics Research Labs, Inc.	Aloe preparation for skin enhancement
US7833829B2 (en) *	2008-10-28	2010-11-16	Honeywell International Inc.	MEMS devices and methods of assembling micro electromechanical systems (MEMS)
US9511125B2 (en) *	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
WO2011079260A2 (en) *	2009-12-23	2011-06-30	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Stabilized virus like particles having enhanced mucosal immunogenicity
US8604187B2 (en) *	2010-01-14	2013-12-10	North Texas Medical Associates	Compositions and methods of aloe polysaccharides
WO2011146635A1 (en) *	2010-05-21	2011-11-24	North Texas Medical Associates	Malignant neoplasm treatment protocol
NZ720863A (en) *	2010-07-23	2016-10-28	Bespoke Bioscience Llc	Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment
WO2012094010A1 (en) *	2011-01-06	2012-07-12	North Texas Medical Associates	Compositions and methods of aloe polysaccharides
US9327029B2 (en)	2011-05-05	2016-05-03	Celacare Technologies, Llc	Antimicrobial silver hydrogel composition for the treatment of burns and wounds
JP6129947B2 (ja) *	2015-12-28	2017-05-17	ビスポークバイオサイエンス，エルエルシー	アロエ多糖体の組成物及び方法
CN112533614A (zh)	2018-03-28	2021-03-19	美国康宝莱国际公司	多糖的乙酰化
CA3198918A1 (en)	2020-10-21	2022-04-28	2Qr Research B.V.	Aloe extracts for microbial neutralisation
IL316508B2 (en) *	2024-10-22	2026-04-01	Moshe YOSHAY Ido	Fermented and dried product based on aloe vera gel and process for its preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3892853A (en) *	1967-05-22	1975-07-01	Aloe 99 & 0 Inc	Stabilized aloe vera gel and preparation of same
US3470109A (en) *	1968-01-31	1969-09-30	Aloe Creme Lab Inc	Method of making reconstitutable aloe gel in crystalline form
US4178372A (en) *	1978-03-06	1979-12-11	Coats Billy C	Hypoallergenic stabilized aloe vera gel
US4851224A (en) *	1986-06-05	1989-07-25	Carrington Laboratories, Inc.	Process for preparation of aloe products
US5106616A (en) *	1988-01-14	1992-04-21	Carrington Laboratories, Inc.	Administration of acemannan
US4555987A (en) *	1983-07-22	1985-12-03	Tumlinson Larry N	Method and apparatus for extraction of aloe vera gel
DE3447572A1 (de) *	1984-12-22	1986-07-03	Wolfgang Wirth	Mittel zur regenerierung und staerkung tierischer und menschlicher organismen koerpereigener abwehrkraefte und der haut sowie zu deren schutz aus aloe-wirkstoffen
JPS61233627A (ja) *	1985-04-10	1986-10-17	Agency Of Ind Science & Technol	肥満細胞脱顆粒抑制剤
JPS63501221A (ja) *	1985-06-28	1988-05-12	カ−リントン　ラボラトリ−ズ　インコ−ポレ−テツド	アロエ製品の製造方法、該方法によって得られた製品およびその組成物
WO1987000052A1 (en) *	1985-06-28	1987-01-15	Carrington Laboratories, Inc.	Processes for preparation of aloe products, products produced thereby and compositions thereof
ZA93216B (en) *	1992-01-17	1993-08-18	Solvay Animal Health Inc	Vaccine containing acemannan as an adjuvant.

1988
- 1988-08-05 US US07/229,164 patent/US5106616A/en not_active Expired - Lifetime
1989
- 1989-08-03 AU AU43194/89A patent/AU637985B2/en not_active Ceased
- 1989-08-03 CA CA000607449A patent/CA1336581C/en not_active Expired - Lifetime
- 1989-08-03 DE DE68920019T patent/DE68920019T2/de not_active Expired - Fee Related
- 1989-08-03 EP EP97119661A patent/EP0857485A3/de not_active Withdrawn
- 1989-08-03 JP JP1509805A patent/JP2888249B2/ja not_active Expired - Fee Related
- 1989-08-03 AT AT89910539T patent/ATE115405T1/de not_active IP Right Cessation
- 1989-08-03 EP EP99115500A patent/EP0965345A3/de not_active Withdrawn
- 1989-08-03 DE DE68929208T patent/DE68929208T2/de not_active Expired - Fee Related
- 1989-08-03 AT AT94105182T patent/ATE192653T1/de not_active IP Right Cessation
- 1989-08-03 EP EP89910539A patent/EP0382840B1/de not_active Expired - Lifetime
- 1989-08-03 EP EP94105182A patent/EP0619117B1/de not_active Expired - Lifetime
- 1989-08-03 WO PCT/US1989/003381 patent/WO1990001253A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP0857485A3 (de)	1999-03-24
US5106616A (en)	1992-04-21
AU637985B2 (en)	1993-06-17
AU4319489A (en)	1990-03-05
WO1990001253A1 (en)	1990-02-22
DE68920019D1 (de)	1995-01-26
DE68920019T2 (de)	1995-04-20
JP2888249B2 (ja)	1999-05-10
DE68929208D1 (de)	2000-06-15
ATE115405T1 (de)	1994-12-15
EP0382840A1 (de)	1990-08-22
EP0619117A3 (de)	1994-12-21
EP0965345A2 (de)	1999-12-22
EP0857485A2 (de)	1998-08-12
EP0619117B1 (de)	2000-05-10
JPH03501624A (ja)	1991-04-11
EP0382840A4 (en)	1991-04-17
EP0382840B1 (de)	1994-12-14
EP0619117A2 (de)	1994-10-12
EP0965345A3 (de)	2000-09-06
CA1336581C (en)	1995-08-08
DE68929208T2 (de)	2000-09-07

Legal Events

Date	Code	Title	Description
2000-09-15	UEP	Publication of translation of european patent specification
2002-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE192653T1 (de)	2000-05-15	Anwendungen von acemannan
DE3876877D1 (de)	1993-02-04	Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ES2132076T3 (es)	1999-08-16	Pirroles sustituidos.
PT789588E (pt)	2005-05-31	Processo para a producao de um medicamento para o tratamento de imunodeficiencia secundaria
PT98371A (pt)	1992-06-30	Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
ES2106784T3 (es)	1997-11-16	Factor de transferencia y metodos de uso.
FI892312A0 (fi)	1989-05-12	Expression av hepatitis b, s och pres2 proteiner i metylotropiska jaester.
DE3850154D1 (de)	1994-07-21	Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE3174765D1 (en)	1986-07-10	High titer production of hepatitis a virus
ATE6402T1 (de)	1984-03-15	Verfahren zur herstellung von hepatitis b oberflaechenantigen.
ATE135905T1 (de)	1996-04-15	Bioadhäsive zusammensetzung und pflaster
ES536055A0 (es)	1986-02-01	Un procedimiento para la produccion de un complejo covalentemente enlazado de heparina-antitrombina-iii
PT88524A (pt)	1988-10-01	Process of preparation of a vaccine for the protection of birdsagainst contagions by mycoplasma and the preparation of a pure culture of the same
NO922456D0 (no)	1992-06-19	Bcrf1-proteiner som inhibitorer av interferon-gamma
ATA145488A (de)	1993-07-15	Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
ATE55250T1 (de)	1990-08-15	Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
FR2610633B1 (fr)	1992-09-18	Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
ATE247474T1 (de)	2003-09-15	Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ATE290012T1 (de)	2005-03-15	Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
FR2589063B1 (fr)	1988-08-26	Procede de culture de babesia canis, application a la preparation d'antigenes et de vaccins, et antigenes et vaccins contre la piroplasmose
SE8800528L (sv)	1988-08-17	Forfarande for att oka effektiviteten for vegetativ forokning av potatis in vitro
DE3869361D1 (de)	1992-04-23	Annaeherung zur herstellung von natuerlicher vitamin e verwendender asymetrischer synthese.
HUT61461A (en)	1993-01-28	Process for producing new pharmaceutical compositions comprising bambuterol
FI871479A0 (fi)	1987-04-03	Menetelmä lääkeaineina käyttökelpoisten perhydrotiatsepiini- ja perhydroatsepiinijohdannaisten valmistamiseksi
ATE48531T1 (de)	1989-12-15	Verfahren zum sterilisieren von rekombinantem mikroorganismus.